Physician profile
Moacir Schnapp
NPI 1043387624
$6,552.09
in general payments reported to CMS, 2019-2025
37 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $704 · 2021: $1,609 · 2022: $1,399 · 2023: $596 · 2024: $527 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,176.01 | 2021-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $810.51 | 2019-2023 | Aimovig |
| Scilex Pharmaceuticals INC. | $404.22 | 2019-2024 | Ztlido |
| Nevro Corp. | $391.97 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $339.72 | 2022 | |
| Daiichi Sankyo INC. | $301.97 | 2019 | |
| Protega Pharmaceutials INC | $289.43 | 2024-2025 | Roxybond |
| Pfizer INC. | $266.34 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $256.51 | 2020-2021 | |
| Lilly USA, LLC | $240.55 | 2019-2023 | Emgality |
| Medtronic USA, INC. | $222.79 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $206.92 | 2019-2021 | |
| Abbott Laboratories | $202.76 | 2023-2025 | Proclaim, Eterna |
| Supernus Pharmaceuticals, INC. | $182.78 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $162.77 | 2019-2023 | Belbuca |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moacir Schnapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.